Please login to the form below

Not currently logged in
Email:
Password:

New head of Lilly oncology

Eli Lilly has appointed Sue Mahony to the role of senior vice president and president of Lilly Oncology

Sue Mahony, currently senior vice president of human resources and diversity, is to become senior vice president and president of Lilly Oncology, replacing John H Johnson, who left the company last month.

Mahony will continue to report to CEO John Lechleiter and will remain on the company's executive committee. Her new position is effective immediately.

Since his departure from Lilly, Johnson has taken over the reins at Savient Pharmaceutical, which is in the process of bringing its gout drug Krystexxa (pegloticase) to market in the US. He was previously CEO of ImClone Systems, and joined Lilly when it acquired the cancer-focused biotech company in 2008.

Steve Fry, currently vice president of human resources for bio-medicines and emerging markets, will take Mahony's old post and will join Lilly's executive leadership team. Fry was managing director of Lilly's Australian affiliate from 2004 to 2007, before becoming executive director of HR for the intercontinental region and Japan. 

Mahony, who has been with Lilly for more than 10 years, was named to the top HR position in 2009. The year before, she had been promoted to serve as general manager of Lilly, following a number of positions in the company's global marketing and new product development operations.

Before joining Lilly, she spent a decade in sales and marketing roles in the UK and Europe in oncology/hematology and cardiovascular medicine for Amgen, Bristol-Myers Squibb (BMS), and Schering-Plough. She holds a PhD in pharmacy from Aston University in the UK, and an MBA from the London Business School. 

Lilly Oncology's portfolio of marketed drugs includes the non-small cell lung cancer treatment Alimta and the ovarian cancer therapy Gemzar. The company has also declared a commitment to developing personalised cancer medications.

11th February 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics